An observational study in Multiple Sclerosis, Long Covid and Healthy, sponsored by Liliana Barrios. Recruiting at 6 sites in Switzerland. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-24.
Sponsored by Liliana Barrios · Observational
Among 142 studies in Multiple Sclerosis with a site in Switzerland — 24 open to participants now, 36 under way, 8 of them phase 3. Multiple Sclerosis · Switzerland.
Among the 142 studies in Multiple Sclerosis with a site in Switzerland, this one is the 30th largest by planned enrollment of the 56 observational ones that give a count, is one of 7 that started in 2026, is one of 56 observational ones, reaches primary completion later than 17 of the 35 other live ones, and was the 139th registered.
3,267 studies on the registry are indexed under Multiple Sclerosis; 662 are open to participants now.
Browse Multiple Sclerosis studies →24 of the 142 studies in Multiple Sclerosis with a site in Switzerland are open now. Recruiting first, the newest first:
Klinik Valens · Sites in Switzerland
Ages 18+
Klinik Valens · Sites in Switzerland
Ages 18+
Prof. Arseny Sokolov, MD, PhD · Sites in Switzerland
Ages 18+
Luzerner Kantonsspital · Sites in Switzerland
Ages 18+
Novartis Pharmaceuticals · Sites in Switzerland, United States, Argentina and 33 more countries
Ages 18–65
A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →
Of the 430 Multiple Sclerosis studies recruiting now, 163 (38%) set no upper age limit and 211 (49%) stop at 75 or younger; 40 take children under 18; 96 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
142 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 17 · Phase 3 31 · Phase 4 10
First in 2002; this study’s year is marked. 7 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 122 is above the median of 100 across 971 observational studies indexed under Multiple Sclerosis.
Median enrollment 141 across the 86 interventional studies, 191 across the 56 observational. Of the 96 that completed or were terminated, 37 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
73 of 142 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Liliana Barrios as lead sponsor.
Liliana Barrios has 1 study filed under Multiple Sclerosis — fewer than ten, so there is no comparison to draw.
6 of the studies in Multiple Sclerosis with a site in Switzerland that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06141473Phase 3SanofiEfficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis | 2027-05-06 |
| NCT07821411Novartis PharmaceuticalsA Real-World Study of Ofatumumab in Multiple Sclerosis Patients in Germany and Japan | 2026-11-30 |
| NCT06854094Ente Ospedaliero Cantonale, BellinzonaConsolidation Therapy With Cladribine in Relapsing Multiple Sclerosis Patients | 2026-12 |
| NCT05009160Research Center for Clinical Neuroimmunology and Neuroscience BaselDreaMS - Validation Study 1 | 2026-12 |
| NCT05357781Insel Gruppe AG, University Hospital BernImmunoglobulin Deficiency a Treatable Cause of Fatigue in Patients With Multiple Sclerosis (MS)? | 2026-12-30 |
Add all 6 to your calendar (.ics) → With an account.
Among the 142 studies in Multiple Sclerosis with a site in Switzerland, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study investigates objective methods to measure and monitor fatigue in patients with post-COVID-19 condition (long COVID) and multiple sclerosis (MS), and includes a group of healthy volunteers for comparison. Fatigue is a common and debilitating symptom of both conditions, but current assessment methods rely mainly on questionnaires, which can be limited by subjectivity and recall bias. The study uses a smartphone application (the FIDO app) together with wearable devices to continuously collect data on fatigue and its fluctuations during daily life, in order to evaluate the potential of digital, objective measures compared to standard assessments.
Participation lasts approximately eight weeks and includes two in-person clinic visits along with a continuous data collection phase. At the initial visit, participants complete baseline assessments and questionnaires and are introduced to the study's digital tools. During the following weeks, participants wear two wearable devices continuously (24 hours a day) and use the FIDO app to complete short daily tasks (approximately 7 minutes every two days) and brief questionnaires (approximately 5 minutes per day). All participants collect a stool sample at home at weeks 4 and 8 for gut microbiome analysis, and complete the Fatigue Scale for Motor and Cognitive Functions at week 4. At the final study visit, participants repeat a subset of the baseline assessments, provide feedback on the digital technology used, and return the study devices.
FIDO is an exploratory, multicenter, observational study evaluating whether fatigue in neurological and post-infectious conditions can be characterized using digital outcomes derived from wearable sensors, smartphone-based performance tests, and self-report collected in free-living conditions.
Fatigue is among the most disabling symptoms reported in multiple sclerosis (MS) and post-COVID-19 condition (long COVID), yet it is assessed almost exclusively through questionnaires administered at single time points in clinic. Such instruments capture neither day-to-day fluctuation nor the exertion-dependent component of fatigue that patients describe. FIDO combines continuous physiological and behavioral monitoring with repeated at-home cognitive and motor testing to examine whether these signals track fatigue as it is experienced in daily life.
The primary focus of the study is feasibility: whether participants in these populations can sustain the required device wear and application-based tasks over an eight-week monitoring period, and how completeness and timeliness of data vary within and between participants. Secondary objectives address the relationship between digital measures and established clinical and self-reported assessments of fatigue, fatigability, autonomic function, and cognition. Further exploratory objectives examine sleep, post-exertional malaise, menstrual cycle phase, gut microbiome composition, machine learning models for estimating and predicting fatigue, the effect of reduced data quantity and resolution on derived measures, and participants' experience and perceived usability of the study tools.
DESIGN AND SETTING
Prospective observational cohort study with three parallel groups and no allocation or intervention. Each participant takes part for approximately eight weeks, comprising two on-site visits and a continuous home-based data collection phase between them.
STUDY PROCEDURES
Visit 1 (baseline). After written informed consent and assignment of a pseudonymized study identifier, participants complete a battery of questionnaires and clinical assessments. Instrumentation includes a 5-lead ECG Holter, an upper-arm blood pressure monitor, an ActiGraph LEAP armband, and a smartwatch. Autonomic function is assessed using a subset of an Ewing-based test battery: heart rate response to paced deep breathing at 0.1 Hz for 10 minutes; the 30:15 ratio on active standing; blood pressure and heart rate response to postural change at 1, 3, and 5 minutes standing; and blood pressure response to a sustained handgrip test at 30% of maximal voluntary contraction for 5 minutes, with blood pressure measured at 1, 3, and 5 minutes. After a two minutes break, blood pressure is measured again. Cognitive, memory, and dexterity assessments comprise the Symbol Digit Modalities Test, the Brief Visuospatial Memory Test-Revised, and the Nine-Hole Peg Test. Participants also perform two administrations each of the smartphone-based cognitive fatigability test (cFAST) and a 30-second finger tapping task, separated by rest periods and preceded by a fatigue visual analogue scale, with the order of the two smartphone tasks counterbalanced. Participants receive the study application, wearable devices and chargers, stool collection kits, printed questionnaires, and device manuals.
Eight-week remote monitoring. Participants wear an ActiGraph LEAP on the upper arm and a smartwatch on the wrist continuously, removing them only for showering and swimming, and synchronize data regularly. Participants with MS receive a Garmin smartwatch and participants with post-COVID-19 condition an Apple Watch; healthy controls receive either model. The application prompts cognitive and motor fatigue visual analogue scales four times daily at random times, morning and evening sleep surveys, and the cFAST and tapping tasks every second day (approximately seven minutes combined). Stress, food, activity, and symptom logging are available on a self-reported basis. The Fatigue Severity Scale is completed weekly by the MS and healthy control groups; it is not administered in the post-COVID-19 group, as the instrument was developed for MS and does not adequately capture fatigue in this population. A printed Fatigue Scale for Motor and Cognitive Functions is completed at week 4. Stool samples for gut microbiome analysis are collected at weeks 4 and 8 and returned by prepaid post.
Visit 2 (final visit). Participants return to their site while continuing to wear the sensors and repeat a subset of the baseline questionnaires, assessments, and smartphone-based tasks. Usability and acceptability questionnaires (UEQ and MARS), completed at home beforehand, are returned, and participants give open verbal feedback during a semi-structured interview, which is audio-recorded. All study devices and chargers are returned at the end of the visit.
Multiple sclerosis participants will be recruited through Bellevue Medical Group (BMG) and NeuroPraxis Zürich during routine clinical visits. External patients may also participate if they have a diagnosis from a recognized medical institution.
Long COVID participants will be recruited from Klinik Lengg during routine clinical visits. External patients may also participate if they have a diagnosis from a recognized medical institution.
Healthy controls will be recruited from the general community in Zurich.
Recruitment across all groups will use physical and digital study flyers; the Long Covid Switzerland association will additionally support flyer distribution. Interested individuals may contact the UZH study team by email or phone to learn about study aims and eligibility; those willing and eligible will be directed to a study site.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Inclusion Criteria Multiple Sclerosis or Long COVID
Inclusion Criteria Healthy:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with a clinically confirmed diagnosis of multiple sclerosis (MS). This group is monitored using two wearable devices and the FIDO smartphone application over two months. At the initial visit this cohort completes demographic questions and the following assessments: the Fatigue Scale for Motor and Cognitive Functions (FSMC), the Hospital Anxiety and Depression Scale (HADS), COMPASS-31, and the Multiple Sclerosis Impact Scale (MSIS-29). The MSIS-29 is administered to this cohort only.
Participants with a clinically confirmed diagnosis of post-COVID-19 condition (Long COVID). This group is monitored using two wearable devices and the FIDO smartphone application over two months. At the initial visit this cohort completes demographic questions and the following assessments: the Fatigue Scale for Motor and Cognitive Functions (FSMC), the Munich Berlin Symptom Questionnaire (MBSQ), the Bell Disability Scale, the Hospital Anxiety and Depression Scale (HADS), and COMPASS-31. The MBSQ and Bell Disability Scale are administered to this cohort only, and characterise symptom severity and functional impairment.
This group is monitored using two wearable devices and the FIDO smartphone application over two months. At the initial visit this cohort completes demographic questions and the following assessments: the Fatigue Scale for Motor and Cognitive Functions (FSMC), the Hospital Anxiety and Depression Scale (HADS), and COMPASS-31.
Percentage of Expected Smartwatch Wear Time Recorded Over Two Months
Passive compliance with continuous smartwatch data collection, as a measure of feasibility of long-term fatigue monitoring. Participants wear a smartwatch continuously for two months: a Garmin smartwatch (multiple sclerosis group), an Apple Watch (post-COVID-19 condition group), or either device (healthy controls). Expected wear time is the full duration of each participant's individual enrolment (approximately 60 days), so the denominator is calculated per participant rather than as a fixed period; charging periods are not excluded, so values are not expected to reach 100%. Compliance is calculated per participant as recorded wear time divided by expected wear time, multiplied by 100. Values range from 0% to 100%, with higher values indicating greater compliance. Compliance is also compared by group, disease characteristics and demographic factors, and baseline characteristics associated with lower compliance are described.
Time frame: 2 months
Percentage of Expected Armband Activity Monitor Wear Time Recorded Over Two Months
Passive compliance with continuous armband data collection, as a measure of feasibility of long-term fatigue monitoring. Participants wear an armband activity monitor (ActiGraph LEAP) continuously for two months. All participants wear the same device, so compliance can be compared between groups independently of device type. Expected wear time is the full duration of each participant's individual enrolment (approximately 60 days), so the denominator is calculated per participant rather than as a fixed period; charging periods are not excluded, so values are not expected to reach 100%. Compliance is calculated per participant as recorded wear time divided by expected wear time, multiplied by 100. Values range from 0% to 100%, with higher values indicating greater compliance. Compliance is also compared by group, disease characteristics and demographic factors, and baseline characteristics associated with lower compliance are described.
Time frame: 2 months
Percentage of Scheduled Study Application Questionnaires Completed Over Two Months
Active compliance with self-reported data collection, as a measure of feasibility of long-term fatigue monitoring. Participants complete short questionnaires in the study smartphone application (FIDO app) over two months, comprising cognitive and motor fatigue visual analogue scales prompted four times daily at random times, morning and evening sleep surveys daily, and the Fatigue Severity Scale weekly in the multiple sclerosis and healthy control groups. The number scheduled follows each participant's individual enrolment (approximately 60 days). Compliance is calculated per participant as the number of questionnaires completed divided by the number scheduled, multiplied by 100. Values range from 0% to 100%, with higher values indicating greater compliance. Compliance is reported per questionnaire type, compared by group, disease characteristics and demographic factors, and baseline characteristics associated with lower compliance are described. Response latency is also evaluated.
Time frame: 2 months
Percentage of Scheduled Study Application Performance Tasks Completed Over Two Months
Active compliance with task-based data collection, as a measure of feasibility of long-term fatigue monitoring. Participants complete two brief performance tasks in the FIDO app approximately every second day over two months: a cognitive fatigability test (cFAST) and a 30-second finger tapping task, together taking approximately seven minutes. The number scheduled follows each participant's individual enrolment (approximately 60 days). Compliance is calculated per participant as the number of sessions completed divided by the number scheduled, multiplied by 100. A session counts as completed if the participant finishes the full task protocol. Values range from 0% to 100%, with higher values indicating greater compliance. Compliance is reported per task, compared by group, disease characteristics and demographic factors, and baseline characteristics associated with lower compliance are described. Response latency is also evaluated.
Time frame: 2 months
Discriminative Accuracy of Cognitive Fatigability Test and Finger Tapping Test Performance for Participant Group, Stratified by Fatigue Level
Participants complete a cognitive fatigability test (cFAST) and a finger tapping test at the study visits and approximately every second day over two months. Performance measures are derived from each test during analysis and are not pre-specified. They are evaluated for their ability to discriminate patients from healthy controls, reported as the area under the receiver operating characteristic curve, from 0.5 (chance) to 1.0 (perfect discrimination), per test. Results are stratified by self-reported fatigue level on the corresponding subscale of the Fatigue Scale for Motor and Cognitive Functions (cognitive subscale for cFAST, motor subscale for tapping; scores 10 to 50, higher indicating greater fatigue). Baseline factors expected to influence this endpoint are age and disease status.
Time frame: 2 months
Reliability and Within-Participant Variability of Cognitive Fatigability Test and Finger Tapping Test Performance
Reliability of smartphone-based performance tests for repeated long-term monitoring. Performance measures are derived during analysis and are not pre-specified. Each test is administered twice in immediate succession, in counterbalanced order, at each of the two study visits, when fatigue is expected to remain stable, and repeated approximately every second day over two months, when fatigue is expected to fluctuate. Agreement across repeated administrations is reported as the intraclass correlation coefficient, from 0 to 1, higher values indicating greater consistency. The immediate-repeat estimate reflects measurement reliability; the two-month estimate reflects the proportion of variance attributable to stable differences between participants. Whether within-participant variation tracks concurrent fatigue is addressed by the corresponding association outcome. Results are reported per test. Baseline factors expected to influence this endpoint are age and disease status.
Time frame: 2 months
Agreement Between Cognitive Fatigability Test and Finger Tapping Test Performance and Established Fatigue and Functional Assessments
Agreement between smartphone-based performance tests and established fatigue and functional assessments. Performance measures are derived during analysis and are not pre-specified. A cognitive or motor fatigue visual analogue scale (0 to 10) is completed immediately before every test session. Performance is additionally compared with the fatigue and functional assessments specified in the protocol, including the Fatigue Severity Scale weekly in the multiple sclerosis and healthy control groups, the Fatigue Scale for Motor and Cognitive Functions at the study visits and at four weeks, the Symbol Digit Modalities Test, the Brief Visuospatial Memory Test-Revised at the initial visit, handgrip strength and the Nine-Hole Peg Test. Associations are reported as correlation coefficients from -1 through 0 to +1, per test pairing. Baseline factors expected to influence this endpoint are age and disease status.
Time frame: 2 months
Association Between Digital Measurements Derived From Wearable Data and the Fatigue Scale for Motor and Cognitive Functions (FSMC)
Association between digital measurements derived from continuously recorded wearable data and the Fatigue Scale for Motor and Cognitive Functions (FSMC). Candidate measurements are derived during analysis from raw sensor signals recorded by an armband monitor and consumer smartwatch, including photoplethysmography, inertial, barometric and temperature signals; their scales are not pre-specified. Associations are reported as correlation coefficients from -1 through 0 to +1, separately for each group.
Time frame: 2 months
Discriminative Accuracy of Armband-Derived Digital Measurements for Distinguishing Patients From Healthy Controls, Stratified by Fatigue Level
Ability of digital measurements derived from continuously recorded armband data to distinguish patients from healthy controls. Candidate measurements are derived during analysis from raw sensor signals recorded by the armband activity monitor (ActiGraph LEAP); their scales are not pre-specified. Only armband-derived measurements are used, because all participants wear the same armband device, whereas the smartwatch differs between groups and would confound comparison between them. Discriminative accuracy for distinguishing patients from healthy controls is reported as the area under the receiver operating characteristic curve, from 0.5 (chance) to 1.0 (perfect discrimination), per derived measurement. Results are stratified by self-reported fatigue level on the Fatigue Scale for Motor and Cognitive Functions (total 20 to 100, higher indicating greater fatigue).
Time frame: 2 months
Performance of Machine Learning Models Trained on Digital Measurements to Estimate Fatigue and Disease Characteristics
Evaluation of machine learning models developed during the project to estimate fatigue and disease characteristics from digital measurements derived from wearable and smartphone data. Models are newly developed for the study's research objectives; no existing models are validated and none is intended for clinical use. Model families and features are not pre-specified. For classification tasks, performance is reported as the area under the receiver operating characteristic curve, from 0.5 (chance) to 1.0 (perfect discrimination). For regression tasks, performance is reported as prediction error against self-reported fatigue scores, with lower error indicating better performance. Performance is estimated using cross-validation with participant-level splits; for personalised models, splits are made within participants over time. Results are reported separately for each group.
Time frame: 2 months
Ability of Wearable-Derived Measures to Detect Autonomic Dysfunction Assessed Against Clinical Autonomic Testing
Whether continuously recorded wearable data can detect autonomic dysfunction. At both study visits participants undergo a standardised autonomic test battery based on Ewing's protocol, recorded using a 5-lead ECG Holter and blood pressure monitor, and complete COMPASS-31 (weighted total 0 to 100, higher indicating greater symptom burden). Metrics derived from continuous photoplethysmography and other armband and smartwatch signals, which are not pre-specified, are compared with these measures and reported as measures of association, from -1 through 0 to +1. Discriminative accuracy for identifying participants classified as having autonomic dysfunction on the battery is reported as the area under the receiver operating characteristic curve, from 0.5 (chance) to 1.0 (perfect discrimination). Autonomic comparisons are reported here rather than under the clinical assessment agreement outcome. Results are reported separately for each group, within which the smartwatch is the same device.
Time frame: 2 months
Association Between Sleep Measures, Sleep Questionnaires and Self-Reported Fatigue
Relationship between sleep and self-reported fatigue. Sleep is assessed subjectively through morning and evening surveys completed daily in the FIDO app, and objectively through measures derived from continuous armband and smartwatch recording, including sleep duration, efficiency, timing and estimated sleep stages; these are derived during analysis and not pre-specified, and stages are estimated rather than measured directly. Both are related to fatigue on the cognitive and motor visual analogue scales (0 to 10, higher indicating greater fatigue) and the fatigue questionnaires collected during the study; the interval between sleep and the fatigue reports it is related to is not pre-specified. They are also compared with each other. Relationships are reported as measures of association, from -1 through 0 to +1, and agreement between sleep measures as the mean difference between methods. Results are reported separately for each group.
Time frame: 2 months
Association Between Digital Measurements and Lifestyle Reporting and Self-Reported State Fatigue
Relationship between continuously recorded digital measurements and self-reported state fatigue. Participants rate cognitive and motor fatigue on a visual analogue scale (0 to 10, higher indicating greater fatigue) four times daily at random times. Digital measurements derived from armband and smartwatch recording, together with lifestyle data logged by participants in the FIDO app at their own initiative, including diet, activity and symptoms, are related to these ratings; the interval between a measurement and the ratings it is related to is not pre-specified, so that measurements preceding a fatigue rating can be examined as possible precursors. Sleep measures and smartphone-based test performance are reported under their own outcomes. Relationships are reported as measures of association, from -1 through 0 to +1, separately for each group.
Time frame: 2 months
Association Between Exertion and Subsequent Post-Exertional Malaise and Symptom Severity in Participants With Post-COVID-19 Condition
Assessment of post-exertional malaise, defined as worsening of symptoms following exertion, in participants with post-COVID-19 condition. Participants log symptoms in the FIDO app at their own initiative, rating severity as low, moderate or high. Measures of exertion and physiological response are derived during analysis from continuous armband and smartwatch recording, including activity, photoplethysmography-derived metrics, blood pressure and skin temperature, and from self-logged activity. These are related to subsequently reported symptom occurrence and severity and to fatigue visual analogue scale ratings (0 to 10, higher indicating greater fatigue), and are considered relative to each participant's usual level; neither the threshold defining exertion nor the interval before subsequent reports is pre-specified. Time since infection, medications and sleep quality are considered as modifying factors. Relationships are reported as measures of association, from -1 through 0 to +1.
Time frame: 2 months
Performance of Machine Learning Models Trained to Predict Self-Reported State Fatigue Fluctuations
Evaluation of machine learning models developed during the project to predict short-term fluctuations in self-reported state fatigue from digital measurements and lifestyle reporting. Models may use measurements recorded before the fatigue rating being predicted, to assess whether objective signals precede fatigue episodes. Models are newly developed for the study's research objectives; no existing models are validated and none is intended for clinical use. Model families and features are not pre-specified. For classification of high versus low fatigue states, performance is reported as the area under the receiver operating characteristic curve, from 0.5 (chance) to 1.0 (perfect discrimination). For continuous prediction of fatigue ratings (0 to 10), performance is reported as prediction error, with lower error indicating better performance. Cross-validation uses participant-level splits. Results are reported separately for each group.
Time frame: 2 months
Association Between Digital Measurements Derived From Wearable Data and the Fatigue Severity Scale (FSS)
Association between digital measurements derived from continuously recorded wearable data and the Fatigue Severity Scale (FSS). Candidate measurements are derived during analysis from raw sensor signals recorded by an armband monitor and a consumer smartwatch, including photoplethysmography, inertial, barometric and temperature signals; their scales are not pre-specified. The FSS is administered only to participants in the multiple sclerosis and healthy control groups; associations are reported for these groups as correlation coefficients from -1 through 0 to +1.
Time frame: 2 months
Effect of Data Amount, Granularity and Missing Data on Digital Measurements of Fatigue and Disease Characteristics
Post hoc analysis of how the amount, resolution and completeness of recorded data affect the digital biomarker outcomes for fatigue and disease characteristics. The recorded dataset is resampled at reduced temporal resolutions, with increasing proportions of data removed, and truncated to shorter recording durations, simulating lower-specification devices, less frequent synchronisation and shorter wear periods. Digital measurements derived from these reduced datasets are compared with those derived from the full dataset, and agreement is reported as correlation coefficients from -1 through 0 to +1. For truncation, the outcome is additionally the number of days after which a measurement no longer changes by more than a predefined margin. Machine learning models trained on the reduced datasets are compared with those trained on the full dataset using the same metrics. Results are reported separately for each group, and inform the design of data collection in future studies.
Time frame: 2 months
Association Between Menstrual Cycle Phase and Self-Reported Fatigue and Digital Measurements
Assessment of whether menstrual cycle phase is associated with fatigue in participants who menstruate. The dates of the most recent menstrual period are recorded at the initial visit and cycle dates covering the recording period by questionnaire at the final visit; phase is estimated from these as follicular or luteal, with continuous wearable measurements used to corroborate self-reported phase. Hormonal contraceptive use is recorded at baseline and accounted for, as it may suppress or alter cyclical variation; perimenopausal and postmenopausal participants are considered separately; and cycle regularity may be affected by the conditions studied, which is taken into account when interpreting phase estimates. Phase is related to fatigue on the visual analogue scale (0 to 10) and the Fatigue Severity Scale (score 1 to 7), higher values indicating greater fatigue, and to digital measurements. Associations are reported as measures of association, from -1 through 0 to +1.
Time frame: 2 months
Gut Microbiome Composition and Differences Between Participant Groups
Characterisation of gut microbiome composition and its variation between clinical groups. Participants collect stool samples at four and eight weeks after the initial visit, which are analysed for microbial composition, summarised as within-sample (alpha) diversity, between-sample (beta) diversity and relative abundance of bacterial taxa. Differences in these measures are examined between participants with multiple sclerosis, participants with post-COVID-19 condition and healthy controls. Participant characteristics that may alter composition are recorded and reported, including medication use such as antibiotics, dietary and lifestyle changes recorded through the diary function of the FIDO app, body mass index, time since disease onset or acute SARS-CoV-2 infection, gastrointestinal symptoms and comorbidities. Values are averaged across the two sampling points to give a more stable estimate; change between them is also examined.
Time frame: 4 weeks and 8 weeks
Perceived Usability of the FIDO App Measured by the User Experience Questionnaire and Mobile Application Rating Scale
Perceived usability and quality of the FIDO app. Before the final visit participants complete the User Experience Questionnaire, yielding six scale scores from -3 to +3 where higher values indicate a more positive experience, and the Mobile Application Rating Scale, yielding four objective quality subscales and a subjective quality subscale, scored 1 to 5 where higher values indicate better quality. The subjective quality subscale covers willingness to recommend the app, expected frequency of future use and overall rating. Associations between usability scores and compliance with scheduled questionnaires and performance tasks are reported as correlation coefficients from -1 through 0 to +1. Results are reported separately for each group.
Time frame: 2 months
Association Between Gut Microbiome Composition and Fatigue, Autonomic Function and App-Logged Diet and Symptoms
Relationship between gut microbiome composition, fatigue and autonomic function. Stool samples collected at four and eight weeks are analysed for microbial composition, summarised as diversity and relative abundance of bacterial taxa, averaged across the two sampling points. These measures are related to fatigue on the Fatigue Scale for Motor and Cognitive Functions (total 20 to 100) and the Fatigue Severity Scale in the multiple sclerosis and healthy control groups (1 to 7), higher values indicating greater fatigue; to autonomic function assessed by COMPASS-31 and a standardised autonomic test battery; to digital measurements derived from wearable data; and to diet and symptom entries logged in the FIDO app. Participant characteristics that may influence composition are reported alongside the associations rather than adjusted for. Associations are reported as measures of association, from -1 through 0 to +1, separately for each group.
Time frame: 2 months
Change in Lifestyle Metrics From the Two Months Before Study Participation to the Two-Month Data Collection Period
Assessment of whether participation in the study, which involves no intervention, was associated with a change in participants' everyday behaviour. Lifestyle metrics recorded by participants' own devices before enrolment, including step count and other activity and sleep measures, are extracted retrospectively from Apple Health for the two months preceding the initial visit and compared with the corresponding metrics recorded during the two-month data collection period. Change is reported as the difference between the two periods for each metric, with positive values indicating an increase during the study. This analysis is possible only for participants who use an Apple device and who consent to sharing historical data, and results are therefore reported for that subgroup and separately for each group.
Time frame: Two months before enrollment and two months during data collection
Participant Experience of Long-Term Digital Monitoring Assessed by Semi-Structured Feedback Interviews
Participant experience of using the FIDO app and wearable devices over two months. At the final visit participants complete a semi-structured interview in German or English, which is audio recorded and transcribed. Transcripts are analysed thematically, covering intention to continue using the app and devices beyond the study, moments of disengagement, barriers to sustained use, sources of motivation, perceived fit of the study design to individual needs, and experience of the wearable devices. Participants also report whether they owned wearable devices before the study and which device placement they preferred, upper arm or wrist; these are reported as counts and proportions. Themes are reported with frequency across participants and illustrative anonymised quotations, examined for differences between the multiple sclerosis, post-COVID-19 condition and healthy control groups, and compared with usability scores and compliance data.
Time frame: 2 months
Association Between Digital Measurements Derived From Wearable Data and the Munich Berlin Symptom Questionnaire (MBSQ)
Association between digital measurements derived from continuously recorded wearable data and the Munich Berlin Symptom Questionnaire (MBSQ). Candidate measurements are derived during analysis from raw sensor signals recorded by an armband monitor and consumer smartwatch, including photoplethysmography, inertial, barometric and temperature signals; their scales are not pre-specified. The MBSQ is administered only to participants in the Post-COVID-19 group; associations are reported for this group as correlation coefficients from -1 through 0 to +1.
Time frame: 2 months
Association Between Digital Measurements Derived From Wearable Data and the Bell Disability Scale
Association between digital measurements derived from continuously recorded wearable data and the Bell Disability Scale. Candidate measurements are derived during analysis from raw sensor signals recorded by an armband monitor and consumer smartwatch, including photoplethysmography, inertial, barometric and temperature signals; their scales are not pre-specified. The Bell Disability Scale is administered only to participants in the Post-COVID-19 group; associations are reported for this group as correlation coefficients from -1 through 0 to +1.
Time frame: 2 months
Association Between Digital Measurements Derived From Wearable and Smartphone Data and the Symbol Digit Modalities Test (SDMT)
Association between digital measurements derived from continuously recorded wearable and smartphone data and the Symbol Digit Modalities Test (SDMT). Candidate measurements are derived during analysis from raw sensor signals recorded by an armband monitor and consumer smartwatch, including photoplethysmography, inertial, barometric and temperature signals, and from smartphone-based measurements collected through the study application. Their scales are not pre-specified. Associations are reported as correlation coefficients from -1 through 0 to +1, separately for each group.
Time frame: 2 months
Association Between Digital Measurements Derived From Wearable and Smartphone Data and the Brief Visuospatial Memory Test-Revised (BVMT-R)
Association between digital measurements derived from continuously recorded wearable data and from smartphone-based assessments and the Brief Visuospatial Memory Test-Revised (BVMT-R). Candidate measurements are derived during analysis from raw sensor signals recorded by an armband monitor and consumer smartwatch, including photoplethysmography, inertial, barometric and temperature signals, and from smartphone-based active tasks and questionnaires administered through the study application; their scales are not pre-specified. Associations are reported as correlation coefficients from -1 through 0 to +1, separately for each group.
Time frame: 2 months
Autonomic Function and Symptoms in Participants With Multiple Sclerosis, Post-COVID-19 Condition and Healthy Controls
Characterisation of autonomic function and its variation between clinical groups. At both study visits participants undergo a standardised autonomic test battery based on Ewing's protocol, comprising heart rate response to paced deep breathing at 0.1 Hz, the 30:15 ratio on active standing, blood pressure response to postural change, and blood pressure response to sustained handgrip at 30% of maximal voluntary contraction, recorded using a 5-lead ECG Holter and blood pressure monitor. Autonomic symptoms are assessed by COMPASS-31 (weighted total 0 to 100, higher indicating greater symptom burden). Values from each component of the battery are compared between participants with multiple sclerosis, participants with post-COVID-19 condition and healthy controls.
Time frame: Baseline and 8 weeks
Agreement Between Blood Pressure Estimated From the Armband Activity Monitor and Cuff-Measured Blood Pressure During Clinical Autonomic Testing
Whether blood pressure estimated from photoplethysmography by the armband activity monitor (ActiGraph LEAP), worn on the upper arm, agrees with cuff-measured blood pressure. Comparison is made only at the study visits, during the autonomic test battery, when cuff blood pressure is recorded in the supine position, at one, three and five minutes of standing, and before, during and after a five-minute sustained handgrip contraction at 30% of maximal voluntary contraction. Estimated and cuff-measured systolic and diastolic blood pressure are compared at each of these timepoints, in millimetres of mercury. Agreement is assessed using Bland-Altman analysis and reported as the mean difference between methods with 95% limits of agreement. Agreement during postural change and sustained contraction, when blood pressure is expected to vary, is examined separately.
Time frame: Baseline visits
Time From Notification to Completion of Scheduled Study Application Questionnaires and Performance Tasks Over Two Months
Responsiveness to scheduled prompts, as a measure of the effort required to sustain active data collection rather than whether it is completed at all. The FIDO app records the time at which each prompt is sent and the time at which the corresponding questionnaire or task is submitted; latency is the interval between these timestamps, in minutes, calculated per completed prompt, with longer intervals indicating slower responding. Prompts that are never completed are not assigned a latency and are captured by the completion rate outcomes. Latency is summarised per participant as the median and as within-participant variability over the two-month period, reported separately for each prompt type (fatigue visual analogue scale, sleep surveys, Fatigue Severity Scale, cognitive fatigability test, finger tapping task), and compared by group, disease characteristics and demographic factors.
Time frame: 2 months
Plan to share: Undecided — A decision on whether individual participant data will be shared has not yet been made. Some participants separately and voluntarily consent to future re-use of their coded data in other research projects (including abroad), distinct from participation in this study itself. However, this consent is not tied specifically to data underlying published results, and no defined external data request process, repository, or access mechanism has yet been established. A decision may be made at a later stage of the project.
Started May 2026 (actual). Primary completion is estimated for May 2028, 23 months after the start.
Of 335 non-industry observational studies under Multiple Sclerosis, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 81. This study's planned 23 months is below that.
Counting every sponsor, half of 426 studies reached it within 41 months; a quarter within 15 and three quarters within 75.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.